Skip to main content

Table 1 Patient demographics at baseline (Safety population)

From: Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

  

Oxycodone PR

(n = 295)

Oxycodone PR/naloxone PR

(n = 292)

Total

(n = 587)

Age (years)

Mean (SD)

58.3 (11.52)

57.5 (11.27)

57.9 (11.40)

 

Median

58

58

58

 

Min, Max

25, 87

29, 84

25, 87

Age group, n (%)

≤ 65

216 (73.2)

221 (75.7)

437 (74.4)

 

> 65

79 (26.8)

71 (24.3)

150 (25.6)

Sex, n (%)

Male

108 (36.6)

102 (34.9)

210 (35.8)

 

Female

187 (63.4)

190 (65.1)

377 (64.2)

Race, n (%)

Caucasian

293 (99.3)

292 (100.0)

585 (99.7)

 

Black

1 (0.3)

0 (0.0)

1 (0.2)

 

Other

1 (0.3)

0 (0.0)

1 (0.2)

Weight (kg)

Mean (SD)

84.7 (20.52)

84.2 (18.03)

84.4 (19.31)

 

Median

83

80.6

82

 

Min, Max

44, 174

47.5, 147

44, 174

  1. PR = prolonged-release; SD = standard deviation